Stocks finish higher Tuesday as the Federal Reserve begins its two-day policy meeting amid bets on faster and deeper near-term rate hikes.

"I will be leaving at a time of promise for Biogen, with noteworthy potential for value creation," said departing CEO Michel Vounatsos.

A Medicare policy decision might hurt sales of this biotech giant's Alzheimer's drug.

Biogen will stop developing a drug to treat a severe neurodegenerative disease, as it did not show sufficient benefit when tested in trials.

A brief snapshot of some medical breakthroughs that are among the costliest in the world.

Sequoia Capital and Y Combinator have told startups that cutting costs is a priority.

Elon Musk will soon allow Dogecoin to purchase SpaceX merchandise.

The theme park company has opened Guardians of the Galaxy: Cosmic Rewind and not everyone is happy despite the ride getting wonderful reviews.

Aurora is slashing its production capacity as it builds a runway toward positive Ebitda a year from now.